Pharmafile Logo
Pharmafocus logo
Advanced Search
gsk_corp_hq_brentford_2

GSK says long-term study for Nucala backs safety profile

March 8, 2016
Manufacturing and Production, Research and Development GSK, GlaxoSmithKline, Nucala, asthma

UK pharma major GlaxoSmithKline (LSE: GSK) said its asthma drug, Nucala (mepolizumab) showed a similar safety profile in a long-term …

News
ema_logo

EMA launches PRIME scheme

March 8, 2016
Manufacturing and Production, Research and Development EMA, Guido Rasi, PRIME

The European Medicines Agency (EMA) has launched its new PRIME (priority medicines) scheme, which aims to strengthen support to medicines …

News
astrazeneca_plaque

AstraZeneca’s Faslodex gets US FDA nod in combination treatment for breast cancer

March 8, 2016
Manufacturing and Production, Research and Development AstraZeneca, Faslodex, US FDA, palbociclib

UK drug-maker AstraZeneca said the US Food and Drug Administration (FDA) has approved a new indication expanding the use of …

News
bms

BMS criticises Scottish regulator over Opdivo skin cancer ‘no’

March 7, 2016
Medical Communications, Research and Development Bristol-Myers Sqibb, NICE, SMC, melanoma, opdivo

Bristol-Myers Squibb says the Scottish Medicines Consortium’s (SMC) decision not to recommend its immunotherapy Opdivo (nivolumab) as a monotherapy for …

News
abbvie_0

AbbVie’s Imbruvica gets US FDA okay as first-line treatment for CLL

March 7, 2016
Sales and Marketing AbbVie, Janssen, Janssen Biotech, US FDA, imbruvica

Drug maker AbbVie said the US Food and Drug Administration (FDA) has approved its Imbruvica (ibrutinib) as a first-line treatment …

News
eli_lilly

Eli Lilly’s plaque psoriasis treatment impresses in Phase III trials

March 7, 2016
Research and Development, Sales and Marketing Eli Lilly, Enbrel, ixekizumab, psoriasis

Eli Lilly has announced late-stage trial data showing ixekuzimab treatment resulted in clinically meaningful improvements in as early as one …

News
rd_hands

Japan’s Ono Pharma focusing on building immuno-oncology portfolio with Opdivo

March 7, 2016
Sales and Marketing Bristol-Myers Sqibb, Ono Pharma, immuno-oncology, opdivo

Japan’s Ono Pharmaceutical has said it is focused on building on its immuno-oncology portfolio following the success of its PD-1 …

News
novo_nordisk

Novo Nordisk reports five-year Victoza cardiovascular safety data

March 7, 2016
Research and Development, Sales and Marketing Novo Nordisk, Victoza

Novo Nordisk has announced the top-line results from a trial investigating the cardiovascular safety of Victoza (liraglutide [rDNA origin] injection) …

News
csl_behring

FDA approves CSL Behring’s new haemophilia B treatment

March 7, 2016
Research and Development, Sales and Marketing CSL Behring, haemophilia

The US Food and Drug Administration (FDA) has approved CSL Behring’s Idelvion (Coagulation Factor IX (Recombinant)), a novel, long-acting albumin …

News

Novartis says its psoriasis drug bests Janssen’s in comparison study

March 7, 2016
Research and Development, Sales and Marketing Cosentyx, Novartis, Stelara

Novartis has announced new data from a study comparing its drug Cosentyx to Janssen’s Stelara, which it says demonstrates Cosentyx’s …

News
teva_copy

Teva suffers EpiPen generic setback after FDA rejection

March 4, 2016
Medical Communications, Research and Development FDA, Teva, analphylaxis, approval, auto injector, auto-injector, rejection

The release of Teva Pharmaceuticals generic for the anaphylaxis treatment, EpiPen (epinephrine), is now expected to be severely delayed after …

News
rd_hands

BioMarin reports positive early-stage results for trial drug to treat CLN2 disease

March 4, 2016
Medical Communications

Biotechnology firm BioMarin Pharmaceutical has announced positive results from early stage trial for drug to treat neurodegenerative disease in children.  …

News
merck_logo_blue_rgb

Merck & Pfizer tie-up with Verastem to develop ovarian cancer drug

March 4, 2016
Medical Communications

German drug major Merck along with Pfizer has joined forces with Verastem to develop the trial drug candidate avelumab to …

News
sanofi_logo_vertical_2011_4colors

Sanofi Genzyme present positive Phase 2 results for fatal neuromuscular disease treatment

March 4, 2016
Medical Communications, Research and Development Pompe disease, Sanofi, clinical trial, neuromuscular, phase 2

Sanofi Genzyme, the branch of the French-based pharma company that focuses on diseases difficult to diagnose and treat, have published …

News
magic_bullets_pills

Almost half of US physicians will prescribe more biosimilars, according to survey

March 4, 2016
Medical Communications Obama, US, biosimilar, patent, prescribing

New data published by InCrowd has suggested that US physicians are very amenable to the prescription of biosimilars, with some …

News
baxalta

Baxalta seeks European marketing rights for haemophilia drug

March 3, 2016
Research and Development, Sales and Marketing Adynovi haemophilia a, Baxalta

Baxalta says it has filed for marketing authorisation for its haemophilia drug Adynovi with European regulators. The European Medicines Agency …

News
ucb_logo_and_chief_executive

UCB targets regulatory filing for its osteoporosis drug in 2016

March 3, 2016
Medical Communications, Research and Development, Sales and Marketing Romosozumab, UCB Pharma, osteoporosis

Belgian drug company UCB says it is looking at a regulatory filing for its trial drug romosozumab to treat osteoporosis …

News
the_european_molecular_biology_laboratory

Merck announces drug discovery collaboration with European Molecular Biology Laboratory

March 3, 2016
Research and Development Cancer, Merck, biomarkers

Merck has announced that it has entered into a research collaboration with the European Molecular Biology Laboratory (EMBL), that will …

News
amgen_flag

Amgen sues Novartis over Enbrel biosimilar

March 3, 2016
Research and Development, Sales and Marketing Amgen, Novartis, Sandoz, biosimilars

Amgen has filed a suit in a US court against Novartis’ generics unit Sandoz, in a bid to protect bestselling …

News
deb_jorn

Valeant company group chairman and executive vice president resigns

March 3, 2016
Medical Communications, Sales and Marketing Valeant, appointed, resignation

In an already troubled week for Valeant Pharmaceuticals, the company has now announced that its group chairman and executive vice …

Appointment
The Gateway to Local Adoption Series

Latest content

Study explores genomic testing approach for unexplained infertility

May 14, 2026

Celtic Renewables receives £7m to develop bio-based solvents

May 14, 2026

Synnovis and SOPHiA GENETICS expand liquid biopsy testing in NHS cancer care

May 13, 2026

MHRA to establish Northern Ireland hub for life sciences sector

May 13, 2026

Shilpa Medicare signs manufacturing deal with NXI Therapeutics

May 12, 2026